ClinicalTrials.gg
Active, not recruitingNCT05558332YSTUpdated Apr 14, 2026

Youth Nominated Support Team

An interventional study of Youth-Nominated Support Teams for CHR in Psychosis, Suicide and Health Care Utilization, sponsored by University of California, Irvine. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by University of California, Irvine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.

Planned enrollment
289th of 682
70 · median 60
Started
2025
with 22 others
No phase
338 of 759
57 open now
Primary completion
2026-11
later than 19 of 112 live
Registered
651st of 759
by date

Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 289th largest by planned enrollment of the 682 interventional ones that give a count, is one of 23 that started in 2025, is one of 338 with no phase, reaches primary completion later than 19 of the 112 other live ones, and was the 651st registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 759 studies in Psychotic Disorders with a site in United States, or all of them as a file.
02

Study summary

This study aims to adapt the current Youth-Nominated Support Team (YST) manual used to treat suicide risk for people at clinical high risk for psychosis.

Read the detailed description

Psychotic disorders are characterized by high rates of suicidal ideation and behavior, and the risk for suicide appears to be greatest during the earliest stages of psychosis. A recent meta-analysis showed that the majority of youth at clinical high-risk (CHR) for psychosis experience suicidal ideation, and that approximately one in five make at least one suicide attempt. There are, however, no suicide prevention interventions specifically tailored to the needs of transition-aged youth at CHR, and no current best practice guidelines for how to respond to suicide risk in this population. The Youth-Nominated Support Team (YST) intervention has recently been shown to reduce mortality among adolescents and is potentially highly adaptable within the context of existing CHR services. YST is intended as an adjunctive treatment and is primarily delivered towards support persons rather than the youth themselves, and therefore would not interfere or overlap with the already extensive direct services provided in CHR treatment settings. The proposed project intends to adapt the YST intervention for CHR populations. Specifically, the investigators aim to: (1) adapt YST for CHR based on stakeholder input (i.e., clients, family/friends, clinicians) and to develop a new treatment manual and submit an additional IRB to cover the next two aims -- (2) to implement YST in a single CHR clinic and to revise the intervention based on input from clients, providers, and support person and (3) conduct a pilot randomized clinical trial at four SAMHSA funded CHR sites to test the efficacy of the adapted YST intervention and to identify underlying mechanisms of change. The investigators hypothesize that the revised intervention will be superior to existing practice for the reduction of suicidal ideation and behavior.

03

Conditions studied

  • Psychosis
  • Suicide
  • Health Care Utilization
  • Family Members
04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A person with suicidal ideation in the past 3 months or suicidal attempt in the past year
  • A person who is receiving or has received treatment for psychosis risk symptoms
  • Between the ages of 12-25

Exclusion criteria

Exclusion Criteria:

  • Cannot have participated in the first 2 phases of the study (focus groups and adaption of the YST-CHR manual)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    YST-CHR Group

    This group will recieve the new adapted YST treatment (YST-CHR). Clinicians will administer this treatment. Neither group will be blind.

    Behavioral: Youth-Nominated Support Teams for CHR

  • No intervention
    Treatment as usual

    This group will receive their usual therapy/treatment as usual.

Interventions

  • BehavioralYouth-Nominated Support Teams for CHR

    Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an "add on" to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk.

06

What researchers measure

Primary outcomes

  1. Social Connectedness

    Connectedness will be measured with the 5-item Thwarted Belongingness subscale of the Interpersonal Needs Questionnaire. Scores range from 15-105 and a higher score indicates lower social connectedness.

    Time frame: 3-months after intervention

  2. Increased Hope

    Hopelessness will be measured with the 4-item Beck Hopelessness Scale (BHS). Hopelessness may be a very sensitive indicator of subsequent suicide risk, particularly among youth with psychosis. The total BHS score is a sum of item responses from 0 to 20 such that higher scores reflect higher levels of hopelessness. Scores greater than 14 identify severe hopelessness.

    Time frame: 3-months after intervention

  3. Treatment Engagement

    This will be measured using clinic records of appointment attendance to determine number of therapy sessions attended.

    Time frame: 3-months after intervention

Secondary outcomes

  1. Severity and Intensity of Suicidal Ideation

    This will be drawn from the Columbia Suicide Severity Rating Scale (C-SSRS). The scores range from 0 to 25. Higher scores indicate higher suicide risk symptoms.

    Time frame: Baseline, 6 weeks after intervention, and 3 months after intervention

  2. Severity and Intensity of Suicidal Ideation

    This will also be drawn from the Suicide History of Assessment for People with Psychosis-Spectrum Experiences (SHAPE). This measure is used to query about suicidal thoughts and actions and history with these experiences. It is not scored but used to get a better understanding of the participant's thoughts and feelings related to suicide.

    Time frame: baseline, 6 weeks after intervention, and 3 months after intervention

Other outcomes

  1. Interpersonal Conflict

    Test of Negative Social Exchange (TENSE). Participants score statements on a scale from 0 to 9. Items are summed together to create a composite score. Higher scores on the TENSE indicate higher frequency of negative social exchange.

    Time frame: 3 months after intervention

07

Study locations

1 site
  • The PREVENT Lab, University of California, Irvine
    Irvine, California 92617, United States
08

References and documents

Publications

  • Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53. doi: 10.1001/archpsyc.62.3.247. PubMed 15753237 ↗
  • Bachmann S. Epidemiology of Suicide and the Psychiatric Perspective. Int J Environ Res Public Health. 2018 Jul 6;15(7):1425. doi: 10.3390/ijerph15071425. PubMed 29986446 ↗
  • Bertolote JM, Fleischmann A. Suicide and psychiatric diagnosis: a worldwide perspective. World Psychiatry. 2002 Oct;1(3):181-5. No abstract available. PubMed 16946849 ↗
  • Alaraisanen A, Miettunen J, Rasanen P, Fenton W, Koivumaa-Honkanen HT, Isohanni M. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc Psychiatry Psychiatr Epidemiol. 2009 Dec;44(12):1107-10. doi: 10.1007/s00127-009-0033-5. Epub 2009 Mar 25. PubMed 19319456 ↗
  • Popovic D, Benabarre A, Crespo JM, Goikolea JM, Gonzalez-Pinto A, Gutierrez-Rojas L, Montes JM, Vieta E. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand. 2014 Dec;130(6):418-26. doi: 10.1111/acps.12332. Epub 2014 Sep 18. PubMed 25230813 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 20 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 28, 2022
StartActual
Mar 12, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05558332
Collaborators
University of Maryland, Baltimore County
Responsible party
Jason Eric Schiffman (Director of Clinical Training, University of California, Irvine) — Principal investigator
First posted
Sep 28, 2022
Start date
Mar 12, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion